Stockwinners Market Radar for July 18, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 97.1K shares of Kratos Defense today

20:06 EDT Cathie Wood's ARK Investment bought 1.16M shares of Ginkgo Bioworks today

19:41 EDT Raytheon, Northrop Grumman complete second hypersonic weapon flight test - Raytheon Missiles & Defense, a Raytheon Technologies (RTX) business, in partnership with Northrop Grumman (NOC), "successfully completed its second flight test of the scramjet-powered Hypersonic Air-breathing Weapon Concept, or HAWC, for the Defense Advanced Research Projects Agency and the U.S. Air Force. This flight test applied the data and lessons learned from the first flight to mature the operationally relevant weapon concept design. The test met all primary and secondary objectives, including demonstrating tactical range capabilities. During the flight test, after releasing HAWC from an aircraft and accelerating to hypersonic speeds using the scramjet engine, the vehicle flew a trajectory that engineers designed to intentionally stress the weapon concept to explore its limits and further validate digital performance models. These models, grounded in real-world flight data, are being used to accurately predict and increase performance as the system matures."

19:36 EDT Ocean Power receives DOE award for up to $1.1M - Ocean Power "announced that the U.S. Department of Energy selected the Company for the Phase II development of a next-generation wave energy converter. In the DOE's recently published awards for clean energy Small Business Innovation Research projects, OPT will receive up to $1,097,212 over the next 18-24 months to develop and test a modular and scalable Mass-on-Spring Wave Energy Converter PowerBuoy for reliable powering of autonomous ocean monitoring systems, bringing an entirely new PowerBuoy into our offering."

19:08 EDT Quhuo CFO Wenting Ji to resign - Quhuo "announced that Ms. Wenting Ji, the Company's director and chief financial officer, informed the Company of her intention to resign from her positions as a director and the chief financial officer due to personal reasons. The resignation of Ms. Wenting Ji will become effective on July 18, 2022. Ms. Wenting Ji has confirmed that her resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The board of directors of the Company has appointed Mr. Zhen Ba, co-founder, director and vice president as the chief financial officer, effective on July 18, 2022. Mr. Ba's responsibilities at Quhuo will include corporate finance, tax, funding, reporting directly to Mr. Leslie Yu, Chairman and Chief Executive Officer of Quhuo."

18:16 EDT Medpace CEO buys $3.22M in common stock - In a regulatory filing, Medpace disclosed that its CEO August Troendle bought 22..3K shares of common stock on July 14th in a total transaction size of $3.22M.

18:06 EDT Chase Corporation to acquire NuCera Solutions for $250M - Chase Corporation announced that it has entered into a definitive agreement to acquire NuCera Solutions from SK Capital. NuCera is a recognized in the production and development of highly differentiated specialty polymers and polymerization technologies serving demanding applications, offering products critical to enabling end-product functionality, performance and reliability. NuCera is headquartered in Houston, Texas with its primary production facility based in Barnsdall, Oklahoma and additional international sales offices in France and Singapore. The company employs approximately 130 people globally. For the trailing 12-month period ended April 30, 2022, the company recognized an estimated revenue of $83M with Adjusted EBITDA margins exceeding 25%. NuCera will be acquired for a purchase price of $250M, pending any working capital adjustments and excluding acquisition-related costs. The purchase will be funded by utilizing Chase's existing revolving credit facility and available cash on hand. The transaction is expected to close by the end of the third calendar quarter of 2022, subject to customary closing conditions and regulatory approvals. Chase expects this acquisition to be accretive to earnings within the first year of ownership. Chase will be modestly levered (~1.2x pro-forma net leverage) post acquisition and maintains ongoing financial flexibility.

17:32 EDT APA Corp. sees Q2 international production105 Mboe/d - APA Corp. sees Q2 international adjusted production is forecast to be 105 Mboe/d, compared to guidance of 107 Mboe/d, with the primary variances attributable to the impact of strong Brent oil prices on Egypt PSC volumes and lower gas production in Egypt. This was partially offset by higher production in the North Sea due to a shift in the timing of planned maintenance at the Beryl Field. U.S. production for the period is forecast to be 200 Mboe/d, compared to guidance of 206 Mboe/d. Approximately 4 Mboe/d of the variance is attributable to non-recurring prior period adjustments, primarily related to the performance of non-operated wells. The remainder is associated with mixed production results from certain Austin Chalk wells placed on production during the quarter.

17:24 EDT Ithax Acquisition, Mondee complete business combination - ITHAX Acquisition "announced the completion of its business combination with Mondee Holdings II, Inc., the high-growth, travel technology company and marketplace. In connection with the completion of the business combination, ITHAX has been renamed Mondee Holdings, Inc. and its Class A common stock and warrants are expected to commence trading on the Nasdaq on July 19, 2022 under the ticker symbols "MOND" and "MONDW", respectively."

17:17 EDT Kirkland's announces CFO transition plan - Kirkland's "announced that CFO and COO Nicole Strain will be leaving the Company, effective August 31, 2022. With support from the board of directors, Kirkland's Home has initiated an executive search process for a new CFO.Until the Company names a successor, it will rely on a newly-established Office of the CFO, which will be co-led by Anna Wilhoit, the Company's controller, and Jessica Tatum, senior director of financial planning and analysis. With the CFO transition plan in place, the Company anticipates reporting its fiscal second quarter 2022 results in late August 2022."

17:12 EDT Celcuity announces FDA breakthrough therapy designation for Gedatolisib in HER2 - Celcuity "announced that the FDA has granted gedatolisib Breakthrough Therapy designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor. Gedatolisib is a potential first-in-class pan-PI3K/mTOR inhibitor. Celcuity's breakthrough application was supported by data from a Phase 1b study that assessed the safety, tolerability and clinical activity of gedatolisib in combination with palbociclib and fulvestrant in patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and an aromatase inhibitor."

17:03 EDT BWX says Joel Duling to retire as President of nuclear operations unit - In a regulatory filing, BWX Technologies disclosed that Joel Duling notified BWX Technologies of his decision to retire from his role as President, BWXT Nuclear Operations Group a wholly-owned subsidiary of the Company, effective July 29.

16:32 EDT Nyxoah receives CE Mark for Genio 2.1 - Nyxoah announced that the Dekra Notified Body has approved the use of Nyxoah's next generation Genio 2.1 system for patients in Europe. As with the recent approval of Genio 2.1 by the U.S. FDA for use in the DREAM U.S. IDE pivotal study, this CE mark pertains entirely to the external components of the Genio system and will be available to all patients who have received Genio implants.

16:31 EDT Civeo announces 12-year contract renewal in Canada - Civeo announced that the company has been awarded a contract renewal to continue providing rooms and hospitality services at its Wapasu Lodge in the Canadian oil sands for Imperial Oil Resources Limited. The highlights of the contract award include a 12-year, take-or-pay contract inclusive of daily minimum occupancies that balance rate reductions with a range of planned cost savings initiatives. The new agreement commences November 1, 2022 and will terminate on October 31, 2034. It includes approximately C$500M of guaranteed take-or-pay revenues, as well as significant upside in excess of take-or-pay based on current occupancy levels. Bradley Dodson, Civeo's President and CEO, stated, "Serving Imperial's Kearl operation at our Wapasu Lodge has been a cornerstone of our Canadian business dating back to 2009. Imperial remains a highly valued customer, and we are excited to extend this longstanding relationship. Civeo is committed to ensuring the cost efficiency of our customers' producing assets, and this contract renewal represents an excellent collaboration between two long-term partners to maximize value in the current operating environment in a mutually beneficial way." In conjunction with this contract award, Civeo expects to deploy approximately C$5M in capital, primarily in 2022, which will include renovations and improvements to Wapasu Lodge. Due to this contract renewal and the supporting capital improvements, Civeo is raising its full year 2022 capital expenditure guidance to $24M-$29M.

16:25 EDT Comstock Mining files for new patent covering breakthrough pathways - Comstock announced a significant expansion of its cellulosic technology portfolio by filing for a new patent covering breakthrough pathways to produce renewable diesel, marine, sustainable aviation fuel, or SAF, and gasoline from woody biomass, at dramatically improved yield, efficiency, and cost in comparison to all known methods. These technology advancements enable a new sustainable feedstock capable of neutralizing a substantial share of current U.S. mobility emissions. Renewable fuels provide an opportunity for decarbonization, however, most of the existing U.S. renewable fuel refineries draw from the same limited pool of constrained feedstocks. Comstock's plans to decarbonize with renewable fuels involves abundant feedstocks that are not used, enabling a vast untapped energy source with superior benefits. Based on current performance data, Comstock projects renewable fuel yields exceeding 80 gallons per dry ton, with lifecycle greenhouse gas emissions reductions well exceeding 80% over petroleum.

16:20 EDT Applied Energetics names Chris Donaghey CFO and COO, effective August 1 - Applied Energetics (AERG) announced that Chris Donaghey has been appointed Chief Financial Officer and Chief Operating Officer, effective August 1. In this role, Donaghey will lead all aspects of Applied Energetics financial strategy, performance, reporting and long-range business planning, as well as investor relations, treasury, controller, and audit operations.. He joins Applied Energetics from Science Applications International (SAIC), a defense and government agency technology integrator, where he served as senior vice president and head of corporate development.

16:17 EDT iRhythm chief commercial officer Dave Vort to resign, Chad Patterson to succeed - iRhythm (IRTC) announced that Dave Vort, the company's chief commercial officer, has resigned effective July 25. Vort will continue to serve the company as a strategic advisor and actively engage with the company's leadership team through March 31, 2023. The company also announced that Chad Patterson will join iRhythm's executive leadership team as its new chief commercial officer, managing the company's commercial strategy, operations and execution. Patterson most recently served as chief marketing officer at Dexcom (DXCM), where he played a role in strategic marketing initiatives to drive revenue growth across multiple geographies.

16:16 EDT 8x8 names Suzy Seandel as Chief Accounting Officer - 8x8 "announced the appointment of Suzy Seandel as Senior Vice President and Chief Accounting Officer, reporting to CFO Samuel Wilson. The company also announced that Tim Young has joined 8x8 as Global Vice President, Revenue Operations."

16:14 EDT Applied, Marathon enter hosting contract for 200-MW Bitcoin mining capacity - Applied Blockchain (APLD) has entered into a five-year hosting contract with Marathon Digital (MARA) for 200-Megawatts of Bitcoin mining capacity. The company will provide hosting services for Marathon's Bitcoin miners at Applied Blockchain's owned and operated co-hosting datacenters.

16:12 EDT Onion receives NYSE non-compliance letter regarding ADS trading price - Onion Global announced that, it has received a letter from the New York Stock Exchange, NYSE, dated July 1, 2022, notifying the Company that it is below compliance criteria in connection with the performance of trading price of Onion Global's American depositary shares. Pursuant to applicable NYSE continued listing standards, a company is considered "below criteria" by the NYSE if average closing price of its security is less than $1.00 over a consecutive 30 trading-day period. A review of the current financial condition of the Company by the NYSE shows that as of June 30, 2022, the 30 trading-day average closing share price of the security was $0.93. Accordingly, the Company is now subject to the procedures as outlined in Sections 801 and 802 of the NYSE Listed Company Manual. Since this is the only criteria that the Company has triggered, the procedures outlined in Paras. 802.02 and 802.03 of the NYSE Listed Company Manual do not apply. The Company must bring its share price and average share price back above $1.00 by six months following receipt of the notification.

16:11 EDT IBM CEO says 'balanced growth across our geographies' in Q2 - "In the quarter we delivered good revenue performance with balanced growth across our geographies, driven by client demand for our hybrid cloud and AI offerings. The IBM team executed our strategy well," said Arvind Krishna, IBM chairman and CEO. "With our first half results, we continue to expect full-year revenue growth at the high end of our mid-single digit model."

16:08 EDT Acadia Pharmaceuticals submits NDA to FDA for Rett Syndrome treatment - Acadia Pharmaceuticals Inc. announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. "This is an important step forward for members of the Rett community who face a devastating disease with no approved therapies," said Steve Davis, Chief Executive Officer. "We are grateful to the patients, their families and the physicians who have participated in the trofinetide clinical studies, including our pivotal Phase 3 Lavender study. We look forward to working with the FDA as it evaluates the NDA." The NDA submission is supported by results from the pivotal Phase 3 Lavender(TM) study evaluating the efficacy and safety of trofinetide versus placebo in 187 girls and young women aged 5-20 years with Rett syndrome. The study demonstrated a statistically significant improvement over placebo on the co-primary endpoints, the Rett Syndrome Behaviour Questionnaire change from baseline to 12 weeks and the Clinical Global Impression-Improvement scale score at 12 weeks. The RSBQ is a caregiver assessment of the core symptoms of Rett syndrome and the CGI-I is a global physician assessment of worsening or improving of Rett syndrome. In addition, the study also met its key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist-Social composite score change from baseline to week 12, a caregiver scale of the ability to communicate.

16:05 EDT Ultragenyx provides interim data on GTX-102 study - Ultragenyx provided a program update on GTX-102 for the treatment of Angelman syndrome, or AS, including interim data from the open-label, dose-escalating Phase 1/2 study in pediatric patients who have a genetically confirmed diagnosis of full maternal UBE3A gene deletion. Interim results on nine patients from the U.K./Canada arm and two patients from the U.S. arm of the Phase 1/2 study demonstrate a meaningful improvement in clinical disease and an acceptable safety profile. These interim data supported a protocol amendment to the Phase 1/2 study that was approved by the U.K. and Canadian health authorities in May to initiate additional, new cohorts of patients at higher monthly loading doses. The study has begun to enroll under the amended protocol and has dosed the first patient in these new cohorts. There have been 14 patients to receive treatment thus far, 10 under the U.K. and Canada protocol, and 4 under the U.S. protocol. Of these, 7 patients have received cumulative doses over 20 mg, and 13 patients have over 147 days of exposure to treatment. There have been no treatment-related serious adverse events of any type nor adverse events related to lower extremity weakness observed in these patients. The most common adverse events in the U.K./Canada Cohorts were vomiting, COVID, upper respiratory infection and transient back pain. In the U.S. Cohort, 2 of 4 patients had no adverse events, a third had transient difficulty in sleeping and the fourth patient had emesis, upper respiratory infection, and asymptomatic EBV hepatitis that resolved and the patient resumed dosing. Cerebrospinal fluid, or CSF, protein levels have remained stable throughout the course of the study consistent with absence of inflammation. There was one case of CSF protein elevation in the U.K./Canada protocol that was due to an asymptomatic reactivation of Varicella Zoster Virus. The protein normalized and the patient resumed dosing without any issues. One subject in the U.S. protocol had a single modestly elevated CSF protein that resolved on the subsequent assessment. The "AS Change Scale" and the "AS Severity Scale" are clinician assessments used to assess patients across five domains and overall change. The AS Change Scale is a relative scale of improvement, and the AS Severity Scale is an objective scale with criteria for each change in domain severity. AS Change Scale evaluations at Day 128 show 7 out of 9 patients improved from Baseline in at least 3 of 5 domains and in the overall score. These data are supported by the AS Severity Scale evaluations taken at Baseline and Day 128 where 6 patients exhibited a decrease in severity in at least 2 of 5 domains and in the overall score. Furthermore, one patient from Cohort 4 showed a 2 or 3-point improvement in the AS Severity Scale across all 5 domains at the PMD assessment at Day 170. This suggests continued improvement from Day 128 prior to receiving the fifth dose. These improvements in the AS Change and Severity Scale scores were also supported by the other clinical measurements including the Bayley Scales of Infant and Toddler Development, which is administered by a trained psychologist; the Vineland-3 adaptive behavior scale, which is administered by a clinician; and the Observed Reported Communication Ability, a caregiver-reported questionnaire. AS Change Scale evaluations taken at Baseline and Day 128 in 2 patients show both had relative improvement from baseline in at least 3 of 5 domains and overall. These data were supported by AS Severity Scale evaluations taken at Baseline and Day 128 where both patients exhibited a decrease in severity in at least 2 of 5 domains and overall. Under the new study amendment approved in the U.K. and Canada, additional dose-selection cohorts will sequentially enroll new patients at incrementally higher starting doses ranging from 7.5 to 14 mg based on age. A younger Cohort 6 will begin dosing at 7.5 mg and an older Cohort 7 at 10 mg. Once clinically sufficient efficacy is observed, two expanded cohorts will enroll 20 patients in each age range using the optimal dosing algorithm determined from the dose-selection cohorts. These patients would provide the longer-term efficacy and safety information for the program. Ultragenyx will seek to initiate the amended protocol in the U.S. pending discussions with the FDA. In the maintenance phase, patients from all cohorts will receive treatment with GTX-102 once every 3 months after the patient's last monthly dose of GTX-102, with incremental dose escalations possible to a maximum dose of 14 mg based on achieving an adequate clinical response.

16:01 EDT OFS Credit estimates NAV of $9.89-$9.99 as of June 30 - OFS Credit Company announced the following net asset value estimate as of June 30, 2022. Management's unaudited estimate of the range of our NAV per share of our common stock as of June 30, 2022 is between $9.89 and $9.99. This estimate is not a comprehensive statement of our financial condition or results for the month ended June 30, 2022. This estimate did not undergo the company's typical quarter-end financial closing procedures and was not approved by the company's board of directors.

15:13 EDT CDC says COVID-19 program for cruise ships no longer in effect - The CDC stated on its website: "As of July 18, 2022, CDC's COVID-19 Program for Cruise Ships is no longer in effect. CDC will continue to publish guidance to help cruise ships continue to provide a safer and healthier environment for passengers, crew and communities going forward." Companies in the cruise space include Norwegian Cruise Line (NCLH), Carnival (CCL) and Royal Caribbean (RCL). Reference Link

13:36 EDT Okta names Shibu Ninan Chief Accounting Officer - Okta announced the appointment of Shibu Ninan as Chief Accounting Officer effective August 15. Prior to joining Okta, Ninan served as Vice President, Chief Accounting Officer at Veritas Technologies for the past seven years. Previously, he was the Chief Accounting Officer for Saba Software. Chris Kramer, who has served as Okta's Chief Accounting Officer for the past three years, is joining the company's FP&A team going forward.

12:50 EDT L3Harris awarded up to $700M missile tracking space development contract - L3Harris Technologies said it has been awarded a contract to build the Space Development Agency's Tranche 1 Tracking Layer satellite program to serve as "eyes in the sky" detecting, identifying and tracking advanced missile threats. The contract has a potential total value of $700M. L3Harris will build a 14-vehicle satellite constellation that will include optical communications terminals, infrared mission payloads, Ka-band communications payloads and multiple pointing modes - advanced technology specifically designed to identify and track the fastest missiles known to exist. The program also includes related ground, operations and sustainment support. L3Harris developed four prototype satellites under the SDA's Tracking Layer Tranche 0 award in 2020. The four space vehicles produced under the $193M firm fixed-price contract will launch in 2023.

12:02 EDT Stagwell acquires Apollo Program, terms not disclosed - Stagwell announced the acquisition of Apollo Program, a real-time, AI-powered SaaS platform that uncovers consumer, creative and contextual insights for scaled modern marketing. Apollo will be integrated with Stagwell's data and insights unification tool, Consumer Understanding and Engagement, and is the first acquisition made by the Stagwell Marketing Cloud. Apollo's enterprise technology tools will connect and enrich Stagwell's expansive first-party data universe with millions of behavioral, transactional, and location-based data points to help marketers understand consumer behaviors, motivations, and states of mind. The integration of Apollo with CUE will automate workstreams to translate insights into effective campaigns across messaging, content strategy, and media. Apollo Program was initially incubated within Anomaly, an agency within the Stagwell network. Apollo will continue to be led by its current team including Jim Caruso. Terms of the deal were not disclosed.

12:00 EDT SIGNA Sports United falls -11.7% - SIGNA Sports United is down -11.7%, or -84c to $6.34.

12:00 EDT BP Prudhoe Bay rises 16.2% - BP Prudhoe Bay is up 16.2%, or $2.70 to $19.36.

12:00 EDT North European Oil Royalty Trust rises 21.7% - North European Oil Royalty Trust is up 21.7%, or $2.65 to $14.87.

11:31 EDT General Dynamics' GDIT unit awarded Europe-wide IT, enterprise network contract - General Dynamics Information Technology, a business unit of General Dynamics, announced that it was awarded the Europe-Wide Information Technology and Enterprise Network contract by the 764th Enterprise Sourcing Squadron at Ramstein Air Base, Germany. The single-award, indefinite delivery/indefinite quantity contract has a total ceiling of $908M with a five-year base period and a three-year option. GDIT will support IT and network systems operated by the U.S. Air Forces in Europe. Individual task orders will encompass modernizing and supporting existing infrastructure, networks, systems, operations and maintenance, cybersecurity, as well as managing new requirements and emerging technology, the company said, adding that services will take place at various facilities in Germany, United Kingdom, Italy, Turkey, and the rest of Europe.

11:15 EDT Ford says ordering opens today for 'most powerful F-150 Raptor ever' - Ford announced that ordering opens today for the new 2023 F-150 Raptor R, which it calls "the most powerful F-150 Raptor ever, featuring a new 5.2-liter supercharged V8 that cranks out 700 horsepower and 640 lb.-ft. of torque for even more extreme off-roading." production starts late 2022 at Dearborn Truck Plant, Ford noted. Reference Link

11:00 EDT Waitr Holdings unveils logo for ASAP amid rebrand - Waitr Holdings revealed the logo for ASAP, the soon-to-be new name for the Company as it rebrands and evolves into its broader "deliver anything" model. The company said, "The new ASAP logo design features solid, bold lettering, with the slight tilt of the "A" and separated arrow within it, acting as a nod to moving forward and constant evolution. The new name and logo reflects a fresh and dynamic look that reinforces the company's new vision to 'deliver anything' to consumers - same day - from any type of business, while still paying homage to Waitr's local roots." Once ASAP officially debuts as the new name for the company later this summer, the new logo will be implemented across all physical and digital assets, including: the new app and website, social media platforms, and all sales and marketing materials.

10:40 EDT NTT Data to provide consulting, advisory services for Hawaii's Med-QUEST - NTT DATA was awarded a contract for government consulting and advisory by Hawaii's Med-QUEST Division, the State of Hawaii Medicaid agency serving more than 430,900 Hawaii residents enrolled in Medicaid.

10:06 EDT NetEase Games announces new first party studio Jar of Sparks - NetEase Games announced Jar of Sparks, a new first party studio that will enjoy full creative freedom as part of NetEase Games. Jar of Sparks is led by Jerry Hook, the former Head of Design on Halo Infinite, and has a team of industry veterans who have worked on some of the biggest franchises in video game history. The company said, "Based in Seattle and looking to recruit globally, Jar of Sparks is a new studio with a team of industry leading creators with a desire to build brand new franchises, with all new characters, stories, and worlds, to inspire the imaginations of players all over the world." CEO & Studio Head Jerry Hook, will be joined by Creative Director Paul Crocker, who acted as Lead Narrative Director on the Batman: Arkham trilogy, and as Assistant Creative Director on Halo Infinite; Executive Producer Greg Stone, who worked as a producer on DOOM and Halo Infinite; and Gameplay Director Steve Dyck, who worked as both an Animation Director and a Design Director for many AAA games including the SSX franchise, NBA Street franchise and the Halo franchise and most recently the Character and Combat Director for Halo Infinite.

10:03 EDT Emerson targets 100% renewable electricity by 2030 - Emerson has joined RE100, a global initiative bringing together businesses committed to 100% renewable electricity. This alignment with other sustainability pioneers in the effort led by Climate Group, in partnership with CDP, is the latest step in Emerson's plan to source 100% renewable electricity by 2030. To achieve this 2030 target, Emerson will leverage a broad range of renewable energy sources, including solar, wind, geothermal and hydropower. Due to recent efforts in the renewables procurement space, Emerson anticipates sourcing 25% of its global electricity usage from renewable sources in 2022. The company has also installed on-site renewable electricity generation systems at several facilities worldwide and will expand implementation of these systems going forward. As part of the company's net zero operations objective, Emerson is targeting 100% renewable electricity coverage from contracted electricity sources and on-site generation assets. Electricity usage drives approximately 75% of Emerson's Scope 1 and 2 emissions.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -8.0% - ProShares UltraShort Bloomberg Natural Gas is down -8.0%, or -$1.73 to $19.83.

10:00 EDT Dingdong rises 10.0% - Dingdong is up 10.0%, or 51c to $5.62.

10:00 EDT Natuzzi rises 11.7% - Natuzzi is up 11.7%, or $1.04 to $9.91.

09:50 EDT Global SPAC Partners Co trading resumes

09:47 EDT Fuwei Films enters into agreement, plan of merger with Baijiayun - Fuwei Films and Baijiayun announced that they have entered into an Agreement and Plan of Merger, pursuant to which Baijiayun will merge with a wholly-owned subsidiary of the Company, with Baijiayun being the surviving entity, and the issued and outstanding share capital of Baijiayun will be cancelled in exchange for newly issued shares of the Company on the terms and conditions set forth therein in a transaction exempt from the registration requirements under the Securities Act of 1933. Upon consummation of the Transaction, Baijiayun will become a wholly-owned subsidiary of the Company. Upon completion of the Transaction, the existing Baijiayun shareholders and existing Company shareholders will own approximately 96.79% and 3.21%, respectively, of the outstanding shares of the combined company. Immediately prior to the completion of the Transaction, the Company's ordinary shares will be divided into two classes - Class A ordinary shares and Class B ordinary shares - with different voting powers but equal economic rights. The Company's board of directors (the "Board") has unanimously: approved and declared advisable the Merger Agreement, the other transaction documents and the Transaction determined that the Merger Agreement, the other transaction agreements and the Transaction are in the best interest of the Company and the Company's shareholders, and resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement, the other transaction agreements and the Transaction. The board of directors of Baijiayun has approved the Merger Agreement, the other transaction agreements to which it is a party and the Transaction. The Company and Baijiayun anticipate that the Transaction will be completed in the fourth quarter of 2022, subject to the satisfaction of closing conditions set forth in the Merger Agreement, including among other things, receipt of Company shareholder approval and regulatory approvals and the continuous listing of the Company on the Nasdaq.

09:47 EDT Sunlands Online falls -7.0% - Sunlands Online is down -7.0%, or -40c to $5.30.

09:47 EDT Bank United Corporation rises 8.2% - Bank United Corporation is up 8.2%, or $1.89 to $25.08.

09:47 EDT Universal Compression rises 9.1% - Universal Compression is up 9.1%, or $3.14 to $37.79.

09:45 EDT Global SPAC Partners Co trading halted, volatility trading pause

09:44 EDT Goldman Sachs doesn't see signs of meaningful credit deterioration, says CFO

09:43 EDT Snap introduces Snapchat for Web - In a blog post by Team Snap, Snap said, "Everyday 332M people open Snapchat on their phones, and with our camera, can start conversations with their real friends. Today, we're introducing Snapchat for Web, a new way for our community to stay connected through our camera when they're at their computers. Open your laptop and head to web.snapchat.com using Chrome to start a call or pick up where chats left off on mobile. With more than 100 million Snapchatters using our voice and video calling each month on average, we're excited to offer a new way for our community to keep conversations going on their computers, where they're already working, learning, and browsing. Snapchat for Web includes top messaging features like Chat Reactions and Chat Reply, along with Lenses which will roll out soon. Snapchat for Web is available to Snapchat+ subscribers now in the United States, United Kingdom, and Canada, and Snapchatters across Australia, and New Zealand. We can't wait to bring it to our entire global community soon." Reference Link

09:41 EDT ITHAX Acquisition Corporation (Units) trading resumes

09:38 EDT Suncor enters agreement with Elliott, new board committee to conduct review - Suncor announced that it has entered into an agreement with Elliott Investment Management, pursuant to which Suncor's board of directors will appoint three new independent directors, two of whom will serve on the CEO search committee. The board will also form a new committee to oversee a strategic review of Suncor's downstream retail business. "These actions build on Suncor's ongoing efforts to enhance safety, reliability and operational excellence and to restore Suncor's industry leadership." As part of its agreement with Elliott, Suncor has appointed the following three new independent directors to its Board, effective immediately: Ian Ashby, former president of BHP Billiton's Iron Ore Customer Sector Group; Chris Seasons, former president of Devon Canada and partner with ARC Financial Corporation; and Jackie Sheppard, former executive vice president, Corporate and Legal Affairs with Talisman Energy. Board Chair Michael Wilson said: "Ian, Chris and Jackie bring valuable expertise to the Board, and we are confident Suncor shareholders will benefit greatly from their operational and commercial experience. In addition, the Board's review of the retail business builds on our longstanding commitment to openly consider alternatives to enhance shareholder value and will help ensure the company is well positioned for even greater success and value creation in the future." The agreement with Elliott contains customary standstill, voting and other provisions. In addition, the agreement includes the right for Elliott to nominate an additional director if certain performance criteria relative to peers are not met by December 31, 2022, and if applicable, includes the extension of the standstill for a period of 12 months following such an appointment. Elliott and the company have also entered into an information sharing agreement, pursuant to which Elliott will have the ability to receive information and share its views regarding the CEO search process.

09:36 EDT Goldman Sachs targeting 3% GSIB surcharge, says CEO Solomon

09:33 EDT Goldman Sachs CEO sees more volatility, uncertainty ahead

09:33 EDT Goldman Sachs CEO: Inflation 'deeply entrenched' in economy

09:31 EDT ITHAX Acquisition Corporation (Units) trading halted, volatility trading pause

09:26 EDT Adial to announce topline results of ONWARD Phase 3 trial on July 20 - Adial Pharmaceuticals announced that it plans to report topline results from the Company's ONWARD Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plans to host a conference call at 1 PM Eastern Time on Wednesday.

09:22 EDT Johnson & Johnson general counsel Michael Ullmann to retire - Johnson & Johnson announced that Michael Ullmann will retire from his position as executive VP, general counsel at the end of this year, following 33 years of leadership and service to the company. He will be succeeded in this role by Elizabeth Forminard. Forminard will also be appointed as a member of Johnson & Johnson's executive committee, effective October 17. Ullmann and Forminard will work together during a transition period until Ullmann's retirement at the end of this year. Forminard has been with Johnson & Johnson for 16 years.

09:14 EDT Camber Energy's Viking says USPTO issues office action on patent application - Camber Energy's majority-owned subsidiary, Viking Energy Group announced that Viking's majority-owned subsidiary, Viking Ozone Technology, was advised that the United States Patent & Trademark Office has issued an Office Action in Viking Ozone's pending patent application covering multi-chamber medical waste treatment systems and methods, wherein a number of claims have been found by the Patent office to be allowable. After Amendment and Response, an issued patent will likely follow. This covers Viking Ozone's proprietary methods and devices utilizing Ozone-based treatments. Viking is expected to use this technology in their expansion into medical waste treatment field internationally.

09:12 EDT Marathon Gold reports key stakeholder agreements for Valentine Gold Project - Marathon Gold provides an update on the completion of several important stakeholder agreements and permitting milestones concerning the development of the Valentine Gold Project in central Newfoundland. These are: Completion and signing of a Benefits Agreement between Marathon and the province of Newfoundland and Labrador; Completion and signing of an Outfitter Environmental Effects Monitoring Plan between Marathon and the Newfoundland and Labrador Outfitters Association; Receipt of the Project's Surface Lease; and Completion and acceptance of a provincial Environmental Preview Report for the Project's powerline, and its release from provincial Environmental Assessment. Marathon is pleased to announce a Benefits Agreement with the province of Newfoundland and Labrador has now been completed. The Agreement, which has been signed by the Honourable Andrew Parsons, Minister of Industry, Energy and Technology, represents a commitment by Marathon to maximize the economic benefits of the Project within the province of Newfoundland and Labrador, with a specific emphasis on employment, skills development, contracting, supplier development, and the involvement of groups traditionally under-represented in the mining business. The Agreement establishes overall targets for the employment of provincial residents during the construction and operation of the Project, as well as targets for person-hours within the province for project management, procurement and engineering. Accompanying the Agreement is a Gender Equity, Diversity and Inclusion Plan, which includes employment targets for women, persons with disabilities, visible minorities, and Indigenous persons, and other measures to enhance their access to the economic opportunities associated with the Project. Marathon is also pleased to announce that it has concluded an Outfitters Environmental Effects Monitoring Plan for the Project with the Newfoundland and Labrador Outfitters Association. The OEEMP builds on a Memorandum of Understanding entered into with the NLOA in October 2021. The OEEMP establishes a framework to assess any potential adverse impacts on outfitters' land and resource use in the region of the Project during its construction, operation, and decommissioning, and to monitor the effectiveness of mitigation measures for such impacts outlined during the Project's Environmental Assessment. The OEEMP identifies a variety of wildlife monitoring programs and key performance indicators on potential project-related impacts on outfitting businesses, such as availability of fish and wildlife resources, access, or diminished client experiences. The OEEMP provides for a financial compensation mechanism for economic impacts demonstrated to be caused by Marathon's mining activities. Marathon is also pleased to announce the issuance of the Surface Lease for the Project by the NL Department of Industry, Energy and Technology. This follows the issuance of the Project's Mining Leases on June 13, 2022. The Surface and Mining Leases cover the development of the Marathon and Leprechaun Deposits for a term of 20 years and are issued pursuant to the terms of the NL Mineral Act. Finally, Marathon has been informed by NL Hydro, the provincial electrical utility, that the Environmental Preview Report for the Project's approximately 40 kilometre long power line has been reviewed and accepted by the Environmental Assessment Division of the NL Department of Environment and Climate Change, and subsequently released from its own Environmental Assessment. The construction of the powerline by NL Hydro, between the Project and the Star Lake hydroelectric generating station and pursuant to the terms of an Implementation Agreement with Marathon, can commence following sectoral permitting and release of the Project from its federal Environmental Assessment, which remains ongoing.

09:08 EDT Triller CEO calls for immediate ban of TikTok - Triller calls on CFIUS, President Joe Biden, Congress, and the Department Of Defense to ban TikTok calling it the largest security threat to America in an open letter by CEO and Chairman of Triller Mahi De Silva. The letter read in part, "As the CEO of a global company whose mission is to help creators take control of their destiny in the creator economy, leveraging transformative adaptive technology, I stand with a growing chorus of elected officials, regulators, intelligence officials, other global executives, and consumers who recognize the enormity of the devastating impact of TikTok on our society. The danger signs abound from the leaders of our intelligence community to the most versatile and connected technology journalists. Every American parent needs to ask what this social video app knows about their children and how those signals are used to get a deeper understanding of the location, preferences, and habits of their parents and the entire family. The petaflops of data sent from American TikTok users start with content preferences and location information that can quickly lead to the determination of home ownership, work, and vacation schedules and a host of much more granular data on every aspect of our American lives. Today, we call for every American to remove TikTok from their devices immediately. Additionally, Triller calls on the U.S. government to take immediate action and ban TikTok and its Chinese-owned parent ByteDance. The stakes have never been higher."

09:07 EDT Genentech's satralizumab-mwge granted FDA orphan designation - Genentech's satralizumab-mwge was granted FDA orphan designation as a treatment of N-methyl-D-asparatate receptor antibody autoimmune encephalitis, according to a post to the agency's website. Reference Link

09:05 EDT Tractor Supply announces Kimberley Gardiner as CMO - Tractor Supply (TSCO) announced that Kimberley Gardiner has joined the company as senior VP and chief marketing officer, or CMO, succeeding Christi Korzekwa who previously announced her plans to retire. Gardiner joins Tractor Supply from Volkswagen of America (VWAGY), where she served as chief marketing officer and senior VP since 2020.

09:01 EDT Genius Brands announces dismissal of securities class action lawsuit - Genius Brands announced that on July 15, 2022, the shareholder class action lawsuit against the Company, filed in the United States District Court for the Central District of California, has been dismissed. Commenting on the court's ruling, the company's General Counsel and COO, Mike Jaffa stated, "We are pleased that the court has ruled in our favor. We remain singularly focused on creating timeless animated content and a cutting-edge global distribution system, while growing revenues and assets for our shareholders."

09:01 EDT Arthur J. Gallagher acquires Four Corners Group, terms not disclosed - Arthur J. Gallagher & Co. announced the acquisition of Toronto-based Four Corners Group Inc. Terms of the transaction were not disclosed. Founded in 2007, Four Corners Group is a Canadian executive search firm operating throughout Canada and the United States.

08:59 EDT Bank of America says loan book 'quite well balanced' - Says 92% of loan book investment grade or secured. Average loans up 12% y/y. Says intends to increase dividend in Q3. Says capital levels "remain very strong." Expects to build capital buffer in coming quarters. Sees NII up $900M-$1B in Q3 vs. Q2; expects "faster growth" in Q4.

08:47 EDT Eve Holding reports Halo Aviation as launch customer for UAM solution - Eve Holding announced that it entered into a letter of intent with Halo Aviation, a provider of bespoke private Urban Air Mobility travel services, to collaborate in the development and launch Eve's Urban Air Traffic Management software solution. As part of the agreement, Halo will acquire the software from Eve with the objective of using the software to maximize its UAM operations. It is the first LOI for Eve's state-of-the-art UATM solution, which will unlock the value and network performance of the UAM market to enable the safe scalability of the industry. The companies also intend to develop an operational model to be deployed in specific missions and regions in the United States and the United Kingdom where Halo operates, Eve said in a statement.

08:42 EDT II-VI, Artilux demonstrate a 3D camera for the metaverse - II-VI and Artilux announced a joint demonstration of a next-generation 3D camera with much longer range and higher image resolution to enhance user experience in the metaverse. Investments in the metaverse infrastructure are accelerating and driving the demand for sensors that enable more realistic and immersive virtual experiences. II-VI and Artilux combined their proprietary technologies in indium phosphide semiconductor lasers and GeSi sensor arrays, respectively, to demonstrate a miniature 3D camera that operates in the short-wavelength infrared, at 1380 nm, resulting in significantly higher performance than existing cameras operating at 940 nm. II-VI provided the highly integrated SWIR illumination module comprising InP edge-emitting lasers that deliver up to 2 W of output power and optical diffusers, in surface-mount technology packages for low-cost and high-quality assembly. Artilux's camera features a high-bandwidth and high-quantum-efficiency GeSi SWIR sensor array based on a scalable CMOS technology platform. Combined, the products enable a broad range of depth-sensing applications in consumer and automotive markets.

08:39 EDT ABVC notes estimate of $2.46B global retinal surgical instruments market by 2028 - ABVC Biopharma announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028, growing at a CAGR of 6.08% between 2022 and 2028. This growth is expected to benefit ABVC's development of its medical device, Vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery. The study notes, "The two most prevalent retinal degenerative diseases are - Age-related Macular Degeneration primarily affecting people age 60 and older and Retinitis Pigmentosa which is the most common inherited cause of blindness in people between the ages of 20 and 60 worldwide. Growing instances of retinal disorders in the geriatric population, eye injuries and rising prevalence of diabetic retinopathy are the key driving factors in the retinal surgery devices market."

08:38 EDT Barnes & Noble Education appoints three new directors to board - Barnes & Noble Education announced that it has appointed three new independent directors, Mario Dell'Aera, Jr., Kathryn Eberle Walker and Denise Warren, to the Company's Board of Director , effective immediately. The Company also appointed Rory Wallace, Chief Investment Officer of Outerbridge Capital Management, LLC , to the Board as an independent director as part of its renewed cooperation agreement with Outerbridge. In addition, Lowell W. Robinson and Zachary Levenick have stepped down from the Board, effective immediately. "The appointments of Mario, Kate and Denise are the culmination of a comprehensive search process and marks significant progress on our commitment to refresh the Board with additional skills, experience and diversity," said Vice Admiral John R. Ryan, Chairman of the Board, Barnes & Noble Education. "Each of these directors bring significant and highly relevant experience, providing additional financial, operational and industry expertise to enhance the execution of our strategy." "On behalf of the Board, I would like to thank Lowell and Zack for their valuable contributions and years of service to the Company," continued Vice Admiral Ryan. "We have appreciated their insights and contributions throughout their tenure on the Board, especially as we have navigated the challenges of the pandemic over the last two years. We wish them all the best in their future endeavors." "

08:37 EDT Nano Dimension announces 12.12% ownership of Stratasys - Nano Dimension (NNDM) announced that it owns 12.12% of the outstanding ordinary shares of Stratasys (SSYS). Yoav Stern, Chairman and Chief Executive Officer of Nano Dimension, commented: "The purpose of Nano Dimension in buying Stratasys shares is the formation of a strategic investment in a market-leader which is well established in a relatively seasoned market segment, while Nano Dimension's disruptive technologies in AME and 3D metal printing supply its shareholders with value created by accelerated growth and expansion curves. Hence, an investor in Nano Dimension will gain from its value creation in "blue ocean" type AM sectors plus having strategic upside from investment in Stratasys, which enjoys a commanding presence in large, stable more mature, mostly polymer-based AM technologies. In contrast, Nano Dimension's material development thrusts and business model strategy are centered around metals with electro-mechanical conductive parameters, metals with superior mechanical qualities, dielectric material, and printing of multi-dimensional-electronic devices and mechanical parts.

08:36 EDT Envigo reaches agreement with DOJ, USDA over Cumberland facility investigation - Inotiv announced that Envigo has entered into a settlement with the U.S. Department of Justice and the U.S. Department of Agriculture that resolves an extensive civil and administrative investigation into Envigo's facility in Cumberland, VA. The settlement, which was mutually entered into by all parties involved and approved by the court on July 15, does not require that Envigo pay any fines or penalties to governmental agencies. In addition, it is expressly stated that the settlement is not an admission of liability or wrongdoing by Envigo with regard to its past operation of the Cumberland Facility. The resolution incorporates the transfer plan that was mutually agreed to by the DOJ and Envigo on July 1, 2022 and it concludes all related civil and administrative complaints related to the Cumberland Facility. In addition, the settlement requires that the DOJ and USDA move to dismiss the civil and administrative complaints with prejudice seven days after all the canines vacate the Cumberland Facility pursuant to the Transfer Plan. This resolution follows Inotiv's press release on June 13, in which Inotiv's President and CEP Robert Leasure, Jr., commented, "Since the Envigo acquisition in November 2021, the Cumberland Facility was recognized as needing improvements and investments," and that "the required investments to improve such facility and the lead time to achieve these improvements had recently increased." In the same press release, Inotiv announced its decision to discontinue investment in the Cumberland Facility and shut it down, considering that the sales derived from the site comprise less than 1% of Inotiv total sales and have not contributed to profits in the Company's Research Models and Services segment since its acquisition. This settlement confirms the orderly closure plan of the Cumberland Facility as previously announced in court filings. Inotiv expects that it will take approximately 60 days to close the Cumberland Facility. Following the closure, Envigo will not engage in any activity that requires a USDA license at the site.

08:35 EDT Medicare extends coverage of Natera's Signatera MRD test - Natera announced that it has received written confirmation from the CMS Molecular Diagnostics Services Program that the Signatera molecular residual disease test has met coverage requirements for patients with muscle invasive bladder cancer, effective April 19. "To our knowledge, this represents the first coverage expansion to occur under the foundational local coverage determination for MRD testing in solid tumors, which was published in December 2021." "This is great news for patients with bladder cancer, who face uncertain treatment decisions throughout the patient journey," said Solomon Moshkevich, general manager of oncology at Natera. "This is also a milestone for Natera, representing the first new disease indication to be covered under the foundational LCD. We look forward to working with Medicare and with the oncology community to continue incorporating Signatera MRD assessment into standard care for patients with solid tumors."

08:34 EDT SG Blocks enters fabrication agreement with Moliving Inc. - SG Blocks announced that the company has entered into a fabrication agreement with Moliving Inc. SG Blocks, in March, invested in Moliving and lead its seed investment round. The fabrication agreement is valued at approximately $15M for an initial 60 units, all of which will be sent to Moliving's Hurley House location, an eco-resort located in the sought-after Hudson Valley area. The initial 60 units will be built over a period of approximately three months, with the plan to build all at the SG Waldron Factory.

08:33 EDT Acer Therapeutics resubmits NDA for ACER-001 for treatment of UCDs - Acer Therapeutics announced the resubmission of Acer's New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for ACER-001 for oral suspension for the treatment of patients with urea cycle disorders, UCDs. Acer believes the resubmission addresses in full the items raised by the FDA in the Complete Response Letter, CRL. In June 2022, as previously announced, the FDA issued Acer a CRL stating that satisfactory inspection of its third-party contract packaging manufacturer is required before the ACER-001 NDA may be approved. Acer notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection. FDA did not cite any other approvability issues in the CRL pertaining to the NDA, nor request any additional clinical or pharmacokinetic studies be conducted prior to FDA action. Additional existing nonclinical information as requested by the FDA in the CRL but identified as "not an approvability issue", as well as labeling and other routine updates to the original NDA, were provided in the resubmission of the NDA. "Our team did an outstanding job resubmitting the NDA one month after we received the CRL," said Chris Schelling, Founder & Chief Executive Officer of Acer. "Our third-party contract manufacturing partner has been incredibly responsive and has confirmed that it is ready for inspection. Our manufacturing partner is regarded as a global leader in clinical supply chain and commercial packaging services with more than 70 years of experience. Along with the other requested updates we provided to the FDA in our resubmitted NDA, assuming it is accepted for review, we now look forward to assisting the FDA in the completion of its review of our NDA as soon as possible."

08:32 EDT Synchrony sees FY22 net charge-offs 3.15% - Says strong credit performance in first half is incorporated into forecast for net charge-offs. Sees FY22 loan receivables growth at least 10%. Sees FY22 net interest margin 15.5%. Sees FY22 RSA/average loan receivables 5.25%. Sees FY22 operating expenses $1.05B per quarter. Says sustained strength in purchase volume. Says strong program performance and purchase volume growth continues. Says expects delinquency to rise modestly. Comments and guidance taken from Q2 earnings conference call.

08:29 EDT Siyata Mobile enters agreement with Spain's Azetti Networks - Siyata Mobile announced an agreement with Spain's WIRELESS ZETA TELECOMUNICACIONES to offer the Company's SD7 rugged mission-critical push-to-talk device through Azetti's existing enterprise sales channels.

08:27 EDT GE says GeHealthCare to list on Nasdaq under ticker symbol 'GEHC'

08:27 EDT GE to execute tax-free spinoff of GE Vernova in early 2024

08:26 EDT General Electric unveils brand names for three planned future public companies - GE announced the brand names of the future companies it will create through its planned separation into three global, investment-grade public companies focused on the growth sectors of healthcare, energy, and aviation. GE HealthCare will be the name of GE's healthcare business. GE's existing energy portfolio of businesses, including Renewable Energy, Power, Digital, and Energy Financial Services, will sit together under the brand name GE Vernova. GE Aerospace will be the name of GE's aviation business. Additionally, GE announced that following the completion of the planned spin-off, shares of GE HealthCare will be listed on The Nasdaq Global Select Market under the ticker symbol "GEHC." H. Lawrence Culp, Jr., Chairman and CEO, GE, and CEO, GE Aerospace said, "Today marks a key milestone in GE's plan to become three independent, laser-focused companies. Leveraging GE's multi-billion-dollar global brand gives us a competitive advantage in our end markets, allowing these businesses to win in the future. Built on a foundation of lean and innovation, these brands will continue our mission of building a world that works and provide our customers with an important reminder of the strengths they value in GE." GE intends to execute the tax-free spin-off of GE HealthCare in early 2023. In early 2024, GE plans to execute the tax-free spin-off of GE Vernova, GE's portfolio of energy businesses. Following these planned spin-offs, GE will be an aviation-focused company called GE Aerospace.

08:24 EDT HTG Molecular announces amendment to senior loan facility - HTG Molecular Diagnostics announced it has entered into an amendment of its June 24, 2020 Loan and Security Agreement with Silicon Valley Bank. Under the terms of the amendment, Silicon Valley Bank has agreed to waive the existing minimum liquidity covenant through the remaining term of the LSA in exchange for a partial prepayment of outstanding principal. The remaining principal will continue to amortize through December 2023, the original maturity date of the term loan.

08:20 EDT Sesen Bio trading resumes

08:15 EDT Genetic Technologies launches multi-test in Obstetrics clinic Siles Health - Genetic Technologies announces it is partnering with Melbourne based Siles Health, a leading Obstetrics and Gynaecology practice, to implement geneType Multi-Risk Test as part of their commitment to remain at the forefront of contemporary personalised patient health care. The geneType Multi-Risk Test is a comprehensive solution that enables an understanding of a patient's risk of developing a range of common serious diseases. The geneType Multi-Risk Test looks beyond inherited diseases and identifies sporadic risk which can account for up to 85% of diagnosed cancers in diseases such as breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes. GENE's CEO, Simon Morriss, said, "Adoption of geneType Multi-Risk Test by Siles Health provides GENE with immediate access to an important and expanding group of patients with the opportunity to make a significant improvement in their health outcomes. This partnership also represents another significant milestone along our pathway to the successful commercialisation of geneType Multi-Risk Tests.

08:13 EDT Jerash Holdings to manufacture apparel for Skechers - Jerash Holdings (JRSH) announced the addition of a new lifestyle branded customer, Skechers (SKX), known for its footwear and a growing range of apparel offerings.

08:11 EDT Sono-Tek sees 2023 capex $300,000-$350,000 - Capital expenditures in the first quarter were $54,000 which were invested in ongoing upgrades to the Company's manufacturing facilities. Sono-Tek anticipates capital expenditures will total approximately $300,000 - $350,000 in fiscal year 2023.

08:11 EDT MEI Pharma, Kyowa Kirin publish data from study of zandelisib on patients - MEI Pharma announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancy in The Lancet Oncology. The published data demonstrate that an intermittent dosing regimen of zandelisib resulted in lower cumulative risk of Grade 3 or worse adverse events of special interest compared to a continuous daily dosing regimen without loss of efficacy. The publication, entitled "Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial," is available on the journal website. "The results observed in our Phase 1b study reinforce the potential of zandelisib, an investigational clinical candidate, to provide a well-tolerated clinical profile either as a single-agent or in combination with other therapies without a loss of efficacy via a unique intermittent schedule compared to continuous daily dosing," said Richard Ghalie, M.D., chief medical officer of MEI Pharma. "We remain encouraged by zandelisib's potential as we continue its development using the intermittent schedule as an oral, chemotherapy-free, time-limited, therapeutic option to meet the needs of patients."

08:08 EDT Daxor completes NIH funded I-Corps program for commercialization of CDSS - Daxor Corporation announces that it participated in the National Institute of Health funded Innovation Corps program to accelerate commercialization of Daxor's clinical decision support software to guide fluid management in acute decompensated heart failure. The I-Corps program is a highly-selective immersive, entrepreneurial training program open only to actively-funded NIH grant awardees. The program prepares businesses to accelerate the economic and societal benefits of NIH-funded projects that are ready to move toward commercialization. Participation in this program was funded by the NIH as a NIH Administrative Supplement to Daxor's ongoing NHLBI SBIR grant and disbursed additional funds to the company as well to support its participation in the program.

08:07 EDT AIM ImmunoTech says Jorgl director nominations invalid, files court complaint - AIM ImmunoTech announced that it received a notice on July 8, 2022, from Jonathan Jorgl, an AIM stockholder who first purchased 1,000 AIM shares on June 27, 2022. The Jorgl Notice seeks to nominate a control slate of two individuals for election to the three-member AIM Board of Directors at the 2022 Annual Meeting of Stockholders. The Board has unanimously determined that the Jorgl Notice is invalid due to numerous deficiencies including failure to comply with the Company's bylaws and accordingly has rejected the Jorgl Notice. The Company also announced that it has filed a complaint in the U.S. District Court for the Middle District of Florida, Ocala Division, against seven defendants - including Mr. Jorgl, his nominees Robert Chioini and Michael Rice, as well as Franz Tudor, Todd Deutsch, Ted Kellner and Walter Lautz. AIM believes these individuals have failed to register as a group pursuant to U.S. securities laws and have committed other unlawful actions in the context of their attempt to effectuate a takeover of the Company's Board. Thomas Equels, M.S., J.D., Executive Vice Chairman of the Board, CEO & President, said, "We are taking these actions to protect the rights of all our stockholders. As the Board determined, the Jorgl Notice contains numerous deficiencies and false and misleading statements. Further, the Activist Group is composed of certain individuals with highly questionable and alarming backgrounds - including instances of insider trading, and breaches of corporate fiduciary duties. In this particular situation, they have wantonly disregarded U.S. securities laws by failing to disclose required information and not making necessary filings. Allowing them to usurp control of the Board and the Company via a proxy contest, without paying a significant premium, would be a grave disservice to all stockholders. This type of hostile board takeover would also be highly detrimental to the patients we are striving to bring new life-saving oncology therapies to market to benefit and would jeopardize all the progress AIM's management team has made over the past five years repurposing our lead drug, Ampligen, into oncology - and building upon the positive interim results in published data from preeminent cancer centers, which we are now seeing from our clinical trials. The Activist Group's actions have left us with no choice but to proactively seek relief from the Court. We look forward to a speedy resolution of this matter so that we can return to fully focusing on advancing our pipeline of therapies to benefit patients and enhance stockholder value."

08:06 EDT Hycroft Mining announces 2022-2023 exploration program - Hycroft Mining is pleased to announce its 2022-2023 exploration program. As the company continues the engineering and design work for the next phase of operations, it will be conducting the largest exploration program at the Hycroft Mine in nearly a decade. There has been no exploration drilling at Hycroft since 2014 and, prior to that, drilling was focused on step-out drilling from the known pits for heap leach operations. Today, the company is focusing on the higher-grade opportunities identified in the 2021 program and for the first time at Hycroft, a systematic approach to understanding the genesis of this world class scale deposit, including potential feeder systems. Hycroft is a low-sulfidation, epithermal system with numerous banded quartz veins similar to Midas-style mineralization yet there has been no prior focus on understanding these veins and what they may mean to potential feeder systems. The 2022 - 2023 exploration program at the Hycroft Mine will comprise approximately 125,000 feet of reverse circulation drilling and approximately 20,000 feet of core drilling. The RC drill rig is on site and the core drill rig is expected to arrive on site later in July. The RC drilling is being conducted by National EWP Inc. of Elko, NV and the core drilling will be conducted by First Drilling LLC of Montrose, CO.

08:05 EDT Seelos Therapeutics doses first patient in SLS-005 open label basket study - Seelos Therapeutics announced dosing of the first patient in an open-label basket study of SLS-005 for the treatment of patients with amyotrophic lateral sclerosis in Australia. Seelos plans to conduct this 24-week, open-label basket study in Australia to evaluate the effectiveness of SLS-005 on disease progression and severity, as well as its safety and tolerability, in participants with ALS, spinocerebellar ataxia and Huntington's disease. "Seelos would like to thank our partners in Australia for their hard work in helping us initiate this basket study. We hope to gain valuable insights into the activity of SLS-005 in several devastating neurodegenerative diseases and the open-label design provides a degree of transparency not possible in a blinded study," said Raj Mehra Ph.D., Chairman and CEO of Seelos. "Today we are also very excited to share that the registrational study in the HEALEY platform trial is actively enrolling and at its current pace of enrollment, we currently expect it to be fully enrolled by the end of this quarter."

08:05 EDT Alzamend Neuro receives pre-IND response from FDA for AL001 - Alzamend Neuro announced that it has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug, or IND, application from the FDA. The FDA's response provides a path for Alzamend's planned clinical development of AL001 for the treatment of bipolar disorder, MDD and PTSD. AL001 is a novel lithium-delivery system; specifically, it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with dementia resulting from mild, moderate or severe cognitive impairment caused by Alzheimer's. AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium. In a Phase I relative bioavailability comparison of AL001 to lithium carbonate completed in March, AL001 was shown to provide dose-normalized bioequivalent plasma pharmacokinetics and the observed safety profile was benign. A phase IIA, Multiple Ascending Dose, or MAD, clinical trial for the treatment of dementia related to Alzheimer's is currently underway. Alzamend plans to conduct further studies designed to enable it to ascertain comparative brain penetration and persistence of AL001 to lithium carbonate. These studies are expected to help predict observations seen in pharmacokinetic nonclinical findings to improve treatments in humans, including the potential for AL001 to exhibit lithium dose sparing properties that could mitigate lithium side effects and the current requirement for TDM in blood. Lithium was the first drug that required TDM by regulatory authorities in product labelling because the effective and safe range of therapeutic drug blood concentrations is narrow and well defined for treatment of bipolar disorder when using lithium salts. Excursions above this range can be toxic. Since providing a greater concentration of lithium to the brain while minimizing the amount of the drug delivered to other organs can improve overall safety, AL001 has the potential to provide a safer product compared to currently marketed lithium salts. Based on the FDA's written feedback, Alzamend anticipates filing the INDs for bipolar disorder, MDD and PTSD upon the completion of the current Phase IIA MAD study. This will allow Alzamend to initiate Phase II clinical trials for all three new indications.

08:04 EDT Ducommun announces new credit facility - Ducommun announced that effective July 14, 2022, it entered into a new credit facility consisting of a $250M term loan and a $200M revolving line of credit to replace its existing debt structure. In connection with the transaction, the Company extinguished its existing $140M term loan, its existing $100M unused revolving line of credit, and its other existing $240M term loan, which would have matured in December 2024, December 2024, and November 2025, respectively. The new term loan and new revolving line of credit will mature in July 2027. The initial variable rate on the new term loan is Term SOFR plus 1.625%, subject to adjustments based on the Company's leverage ratio. At the time of extinguishment, the variable rates of the loans being extinguished were LIBOR plus 1.75% on the $140 million term loan, with an outstanding balance of approximately $110M and LIBOR plus 4.00% on the $240 million term loan, with an outstanding balance of approximately $145M. This new credit facility, combined with the forward interest rate swaps the Company entered into in November 2021 for an aggregate total notional amount of $150M that will be effective on January 1, 2024 and expiring on January 1, 2031, locks in key components of the Company's debt management strategy.

08:03 EDT China Pharma reports submission of compliance plan to NYSE American - China Pharma Holdings announced that on July 15, 2022, the company submitted a plan of compliance to NYSE American LLC to address the deficiency in the company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022. As previously released in a press release dated June 22, 2022, according to the Letter, in order to maintain its listing, the company must submit a plan of compliance by July 15, 2022 addressing how it intends to regain compliance with Section 1003(a)(iii) of the company Guide by December 15, 2023. Zhilin Li, China Pharma's Chairman and CEO, commented, "The staff of the NYSE American indicated that they could accept the plan of compliance. During the next 18 months grace period or by December 15, 2023, we will actively supply additional information as required by the Exchange, implement the plan and strive to regain compliance on stockholders' equity as required by the Exchange listing requirement under as soon as possible."

08:02 EDT Eledon Pharmaceuticals doses first patient in Phase 1b trial of tegoprubart - Eledon Pharmaceuticals reported that the first patient has been dosed in a Phase 1b study to evaluate tegoprubart in patients undergoing kidney transplantation. This open-label study, which has received clearance in Canada and the United Kingdom, is enrolling up to 12 patients who will undergo kidney transplantation. The patients will receive tegoprubart in combination with rabbit anti-thymocyte globulin induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. The study will evaluate the safety, pharmacokinetics, and efficacy of tegoprubart, including incidence of biopsy-proven acute rejection, immune cell infiltrate of graft biopsy, and biomarker measures of kidney injury and rejection risk.

08:02 EDT Royal Caribbean acquires cruise ship Endeavor for $275M - Royal Caribbean Group announced it has received court approval to acquire the ultra-luxury cruise ship Endeavor. Originally delivered to Crystal Cruises in 2021, the ship will be renamed Silver Endeavour when it officially joins the Group's wholly owned subsidiary, Silversea Cruises' fleet, this month, the company said in a statement. The purchase price for the vessel was $275M, significantly below the cost of construction. The vessel was fully financed through a 15-year unsecured term loan, guaranteed by the German export credit agency, Euler Hermes, with no amortization payments in the first two years. The acquisition is expected to be immediately accretive to earnings, cash flow and ROIC. "With Endeavour, we are seeking to grow our world class fleet to meet the exceptional demand for ultra-luxury expedition cruising, while also enhancing our profitability profile and affirming Silversea's position as the industry's leading ultra-luxury and expedition cruise line," said Jason Liberty, president and CEO, Royal Caribbean Group.

07:52 EDT Small Pharma appoints George Tziras as CEO, succeeding Peter Rands - Small Pharma announces that the company's board of directors has appointed George Tziras as CEO of the Company, effective as of July 20, 2022. Peter Rands, founder and current CEO, will take on the role of Chief Innovation & Intellectual Property Officer of the Company. Rands will be relocating to the United States as part of a planned succession to better position the business for the later stages of clinical development and establishing the Company's footprint in the United States. Rands will continue to serve on the Board following the transition.Tziras initially joined Small Pharma in 2015 as a director of Small Pharma Ltd, the Company's main operating subsidiary, before also being appointed to the role of CBO and director of the Company in 2021. In relation to Mr. Tziras' appointment as CEO of Small Pharma, the Board has granted him options to purchase up to an aggregate of 1,000,000 common shares in the capital of the Company pursuant to the Company's stock option plan. Each option is exercisable for one Common Share at a price equal to the greater of $0.105 per Common Share; and the closing price of the Common Shares on July 18, 2022, being the first trading day after the release of the Company's financial results. The options are exercisable for a period of ten years and are subject to certain vesting requirements.

07:44 EDT Meta Materials granted patents for battery separators - Meta Materials announced that two new U.S. patents were recently granted directed to second and third generation nanoporous ceramic battery separators. Including new patent filings and the patent portfolio acquired with the Optodot asset acquisition, META now has 410 active patent documents, including 251 issued patents and 159 pending patent applications. META's patent portfolio comprises 98 patent families, of which 57 include at least one issued patent. US Patent No. 11,387,521, issued July 12, 2022, is directed to an advanced nanoporous separator for lithium-ion batteries which has far superior safety properties such as better heat conductivity and non-shrinkage compared to conventional separators currently used in lithium-ion batteries. US Patent No. 11,387,523, issued July 12, 2022, is directed to a new generation lithium-ion battery in which the cathode is directly coated onto the separator. This technology reduces the complexity and expense of the equipment used to fabricate the battery, for flat and prismatic batteries that can be used, for example, in electric vehicles. This US patent also enables alternative manufacturing processes, such as where a non-dried, wet cathode is applied to the separator.

07:41 EDT EyePoint reports preliminary Q2 net product revenue $11.3M - Consensus $10.89M. EyePoint Pharmaceuticals announced the Company will highlight historical and ongoing developments for its lead pipeline program, EYP-1901 and its Durasert platform technology, and will also provide a financial update during its Investor Day, Monday, July 18, 2022, from 8:00 a.m. to 11 a.m. ET. Investor Day Highlights: Nancy Lurker, CEO will present an overview of the Company. Jay Duker M.D., COO will present an overview of EYP-1901 using a bioerodible formulation of EyePoint's proprietary Durasert technology for sustained intraocular drug delivery, which has been safely administered to over 80,000 patients' eyes across four U.S. FDA approved products. Said Saim, Ph.D., CTO, will present an overview of EYP-1901 preclinical data, including its development and formulation and new pre-clinical data highlighting neuroprotection potential for EYP-1901. Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University, will present the 12-month safety and efficacy data from the Phase 1 DAVIO clinical trial evaluating EYP-1901 for the potential treatment of wet AMD that showed continued positive safety and efficacy for EYP-1901 including no serious ocular adverse events and 35% of patients out to 12 months with no supplemental anti-VEGF treatment after the initial EYP-1901 insert was administered. Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, and Jay Duker M.D., COO, will discuss the potential opportunity of EYP-1901 as a "treat to maintain" maintenance therapy for wet AMD. Dario Paggiarino, M.D., CMO will present the EYP-1901 Phase 2 plans in wet AMD and NPDR with first patient dosing anticipated in Q3 2022. He will also provide an update on two ongoing Phase 4 studies for YUTIQ 0.18 mg, for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye. George Elston, CFO, will provide a financial update on Q2 2022 performance with net product revenue of $11.3M for the quarter and cash and investments of $171M at June 30, 2022. He will also discuss the potential impact of the 2023 CMS Draft HOPPS rule released last week in which CMS has indicated its intention not to provide further pass-through extension to expiring products, including DEXYCU. If the draft rule becomes final, DEXYCU will lose pass-through separate reimbursement status on December 31, 2022 and will instead be bundled into the general Cataract procedure reimbursement code starting on January 1, 2023.

07:38 EDT Algoma Steel announces OSC relief in substantial issuer bid - Algoma Steel Group announced that the Ontario Securities Commission has granted an exemptive relief order exempting Algoma from complying with the requirement that Algoma first takes up all of its common shares deposited under its currently underway substantial issuer bid before extending the expiration date of the Offer, if Algoma ultimately determines to extend the Offer in the circumstance where the Offer is undersubscribed. The Offer by Algoma is being made by way of a "modified Dutch Auction", allowing shareholders who choose to participate in the Offer to individually select the price, within a price range of not less than $8.75 and not more than $10.25 per Share, at which they will tender their Shares to the Offer. Upon expiry of the Offer, Algoma will determine the lowest purchase price that will allow it to purchase the maximum number of Shares properly tendered to the Offer, and not properly withdrawn, having an aggregate purchase price not exceeding $400M. The Offer is not conditional upon any minimum number of Shares being tendered. The Offer is, however, subject to other conditions described in the tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal for registered shareholders and related documents, filed by Algoma with the United States Securities and Exchange Commission, and a separate issuer bid circular, letter of transmittal for registered shareholders and related documents, filed by Algoma with Canadian securities regulatory authorities. The Offer is currently open for acceptance until 5:00 pm on July 27, 2022, unless withdrawn, extended or varied by Algoma. The Company reserves the right, in its sole discretion to terminate the Offer and not take up and pay for any Shares not theretofore taken up and paid for upon the occurrence of certain events and at any time or from time to time prior to the Expiration Date, to amend the Offer in any respect, including increasing or decreasing the number of Shares the Company may purchase or the range of prices it may pay pursuant to the Offer, subject to compliance with applicable securities legislation.

07:36 EDT Meta Materials granted two new U.S. patents - Meta Materials announced that two new U.S. patents were recently granted directed to second and third generation nanoporous ceramic battery separators. Including new patent filings and the patent portfolio acquired with the Optodot asset acquisition, Meta now has 410 active patent documents, including 251 issued patents and 159 pending patent applications. Meta's patent portfolio comprises 98 patent families, of which 57 include at least one issued patent. US Patent No. 11,387,521, issued July 12 is directed to an advanced nanoporous separator for lithium-ion batteries which has far superior safety properties such as better heat conductivity and non-shrinkage compared to conventional separators currently used in lithium-ion batteries. US Patent No. 11,387,523, issued July 12, is directed to a new generation lithium-ion battery in which the cathode is directly coated onto the separator. This technology reduces the complexity and expense of the equipment used to fabricate the battery, for flat and prismatic batteries that can be used, for example, in electric vehicles. This U.S. patent also enables alternative manufacturing processes, such as where a non-dried, wet cathode is applied to the separator.

07:36 EDT Vitalhub announces multi-year contract with Buckinghamshire, Oxfordshire - VitalHub announces a multi-year licensing contract of subsidiary Transforming System's SHREWD Platform and SHREWD Resilience offerings to Buckinghamshire, Oxfordshire and Berkshire Integrated Care System. Through this contract, BOB ICS will attain visibility of the entire health system in real time, enabling improved resource utilization, capacity and load balancing, and operational efficiency. This contract provides access to the SHREWD Platform and Resilience offerings across BOB ICS, further increasing penetration of Transforming System's offerings across southeast England. With this deployment, SHREWD products will be installed in four out of the six ICS's in southeast England. The remaining two ICS's both using other VitalHub products, presenting a further organic growth opportunity. "We are delighted with the ongoing progress and deployment of Transforming System's products across the UK," said Dan Matlow, CEO of VitalHub Corp. "The power of real-time visibility solutions offers incredible power to health systems, enabling improved resource utilization, response times, and overall quality of care. We look forward to continuing to expand our presence across the UK and beyond, as we strive to provide best-in-class operational visibility solutions to our clients."

07:34 EDT Bowman Consulting acquires Project Design Consultants - Bowman Consulting announced the purchase of Project Design Consultants, or PDC. Founded in 1976 and headquartered in San Diego, California, PDC and its 65 employees provides civil engineering, surveying, planning and landscape architecture to a variety of public and private clients throughout Southern California. Under the leadership of Greg Shields, the company's CEO, PDC provides engineering services that manage change and add value to infrastructure projects involving public works for municipal agencies, utility service providers, urban and suburban mixed-use developers, hospitality and entertainment venue owners, and commercial and healthcare facility operators. The company expects the PDC acquisition to initially contribute approximately $14M of annualized net service billing and be immediately accretive. Structured as a stock purchase with a joint election under Section 338 of the Internal Revenue Code, the acquisition was financed with a combination of cash and notes including one unsecured seller note and one convertible note with a $14.00 conversion option price.

07:33 EDT PyroGenesis provides update on 3D printing powders business line - PyroGenesis Canada provided an update on its high quality plasma-atomized metal powders business line. PyroGenesis previously announced the filing of a provisional patent for a revolutionary plasma atomized metal powder production process, for use in 3D printing by additive manufacturers. This process was a significant departure from conventional plasma atomization - a technology the Company also invented and coined the term for, and which is still considered the gold standard for the production of metal powder. The provisional patent targets higher production rates, narrower particle size distribution, and has the additional advantage of being able to shift the bulk PSD into a more desirable distribution. These advantages enable the Company to produce for the Additive Manufacturing industry, a very targeted powder, with little to no waste, at higher volumes and lower cost. PyroGenesis has a technical and commercial partnership agreement with Aubert & Duval. This agreement, in place since 2019, pairs PyroGenesis with a partner that has a history of supporting their customers in AM, from the development of product to mass production. The agreement established the framework within which Aubert & Duval and PyroGenesis would work together during the period wherein PyroGenesis developed their NexGen technology. It also provided Aubert & Duval with exclusive rights to market PyroGenesis plasma-atomized titanium powders in Europe, while at the same time agreeing to buy titanium powder exclusively from PyroGenesis With NexGen now producing titanium powder, and with powder shipments now commenced for distribution to companies worldwide for qualification, discussions are now under way between the parties for full distribution agreements. Steps under discussion include, but are not limited to, distribution planning, order planning, and logistics. The Company hopes to provide more information on these developments in the very near future. PyroGenesis also has an agreement with a tier one North American global aerospace company for qualification of the Company's titanium metal powder. Under this agreement, the Client has been performing an in-depth qualification process - a procedure typically required before a company can become an approved supplier. The process was established to, amongst other things, evaluate the Company's manufacturing methods, test samples of powder for batch-to-batch consistency, and determine various mechanical and chemical properties. Subsequently, larger volumes of powder will be used to print test coupons to further evaluate mechanical and chemical properties. Upon passing all steps, including acceptance tests, the Company's process will be locked down specifically for each client, with no additional modifications permitted. Upon successful completion of the testing, PyroGenesis would expect to receive formal acceptance as an approved supplier. Status of Qualification Agreement: The formal and methodical process with this top tier aerospace company is on track and is nearing conclusion. Recently, the Client provided verbal approval of "work instructions" - the procedures given to the Company's factory operators, which serves as the de facto facility operational manual for the Client's specific operating standards and expectations. Next steps include the final assessment and approval of various non-manufacturing processes, for aspects such as quoting, handling, storing, shipping, logistics, etc. As the Company has already achieved ISO 9001:2008 and AS9100D certification, it is confident that these processes will meet the Client's standard, after which the last step is for final small samples to be produced under the final locked-down process state. Once the final sample powder is analyzed, the Client will provide a memo that the Company's titanium metal powder is approved for use upon which the Company will inform investors. The Company anticipates achieving final approval during Q4 of this year, 2022.

07:33 EDT Vishay advances its executive transition plan - Vishay Intertechnology announced that, as part of the Board of Directors' executive transition plan, three executive officers will leave the Company effective December 31, 2022 and two new executive officers have been appointed, effective January 1, 2023. In addition, the Board's independent Compensation Committee has approved employment agreements for the executive management team that include changes to the executive compensation programs. Johan Vandoorn, Executive Vice President - Chief Technical Officer; Clarence Tse, Executive Vice President and Business Head Semiconductors; and, David Valletta, Executive Vice President - Global Sales will leave the Company on December 31, 2022. Tse's responsibilities will be absorbed by Jeff Webster, who was previously appointed by the Board of Directors to the newly created position of Chief Operating Officer effective January 1, 2023. The Company intends to evaluate internal and external candidates to fill the position of Executive Vice President - Global Sales and has engaged a global executive search firm to assist it in this effort. Effective January 1, 2023, Roy Shoshani is promoted to the position of Executive Vice President - Chief Technical Officer, succeeding Vandoorn, and Peter Henrici is promoted to the position of Executive Vice President - Corporate Communications, a newly created role, while continuing to serve as Corporate Secretary. Both Messrs. Shoshani and Henrici will report to Joel Smejkal, who was previously appointed by the Board to succeed Dr. Gerald Paul as President and Chief Executive Officer effective January 1, 2023.

07:32 EDT Sesen Bio announces decision to pause clinical development of Vicineum - Sesen Bio announced that it has made the strategic decision to voluntarily pause further development in the U.S. of its lead asset, Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of non-muscle invasive bladder cancer, or NMIBC, following recent discussions with the FDA. This decision enables Sesen Bio to conserve cash while it continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the company intends to seek a partner for the further development of Vicineum.

07:31 EDT Eton Pharmaceuticals trading halted, news pending

07:27 EDT Goldman Sachs reports Q2 FICC revenue $3.61B

07:26 EDT Goldman Sachs reports Q2 annualized ROE 10.6%, ROTE 11.4% - Reports Q2 book value per share $301.88.

07:17 EDT Idaho Strategic to begin REE drill program at Diamond Creek - Idaho Strategic Resources announced that construction of the first two drill platforms has been completed and drilling is set to begin this week at its Diamond Creek Rare Earth Element Project near Salmon, Idaho. Concurrent with the start of the Company's drill program, the University of Idaho has begun conducting innovative Rare Earth Element separation experiments at their lab using soil and samples collected at Diamond Creek earlier this month as part of the IGEM Program. Idaho Strategic's Diamond Creek Project is in the center of Idaho's 70-mile long Rare Earth Element-Thorium Trend and is centrally located south of the Company's Roberts REE Project in the Mineral Hill District and north of the Company's Lemhi Pass REE - Thorium Project. IDR's 8,000-foot diamond drill program is designed as an initial test for the potential resource of 75,500 tons1 of total REE oxides estimated by the U.S. Geological Survey. Based on current Rare Earth Element price averages over the past 6 months for the historical estimated mix of individual Rare Earth Elements, the potential in-situ value estimate from the historic Diamond Creek numbers is estimated to be over $4B - with nearly half of that value coming from Neodymium. The project objectives for this initial drill program are to locate high concentrations of REE mineralization at Diamond Creek in veins and structures; and to track this REE mineralization to its source. With overall project goals to include defining and delineating the potential for the historic resource numbers to become reality, as the Diamond Creek mineralization estimates have been mentioned in USGS, DOE and other publications. Recent soil analysis by XRF detection at Diamond Creek conducted by IDR's geologists and researchers from the University of Idaho and Idaho National Laboratory measured values to 1,500 ppm Neodymium as well as other Rare Earth Elements. This material was gathered at the surface during the construction of the Company's first two drill pads and will be used by the University of Idaho as a planting medium where hyper-accumulator plants will be grown to study the recovery of Rare Earth Elements; a process referred to as phytomining. The University of Idaho will also be utilizing our samples to study the extraction of REEs through bioleaching. Both phytomining and bioleaching are being looked at as potential net-negative carbon and/or carbon neutral REE processing techniques as part of the IGEM Program. The IGEM Program is funded by the Idaho Commerce Dept. and in partnership with IDR, Idaho National Labs, Idaho Geological Survey, and the Center for Advanced Energy Studies.

07:14 EDT Advent receives official ratification from EU for 'Green HiPo' IPCEI Project - Advent Technologies Holding announces that its Green HiPo projec under the framework of the Important Projects of Common European Interest IPCEI Hydrogen - Technology, has now received official ratification from the European Commission of the European Union . The ratification of Green HiPo was amongst 41 projects under the umbrella "IPCEI Hy2Tech" jointly prepared and notified by fifteen Member States: Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Slovakia, and Spain. The Member States will provide up to EUR 5.4 billion in public funding, which is expected to unlock an additional EUR 8.8 billion in private investments. As part of this IPCEI, 35 companies with activities in one or more Member States, including small and medium-sized enterprises and start-ups, will participate in these 41 projects. Advent is one of only eight SMEs to have received ratification. The direct participants will closely cooperate with each other through numerous planned collaborations and also with more than 300 external partners, such as universities, research organizations, and SMEs across Europe.

07:12 EDT Millicom signs FTTH wholesale network agreement with ETB - Millicom announces that its operation in Colombia has entered into a wholesale network access agreement with Empresa de Telecomunicaciones de Bogota. Under the terms of the agreement, Tigo Colombia will be able to offer Tigo-branded broadband internet, PayTV, telephony and over-the-top services to residential and small business customers using ETB's fiber-to-the-home network, which covers 1.5 million homes in Bogota. When combined with Tigo Colombia's own network infrastructure as well as its other existing wholesale agreements, the landmark partnership with ETB will allow Tigo to reach the vast majority of potential customers in Bogota, the largest city in Colombia. This represents an increase of more than 20% in Tigo Colombia's commercial footprint for its suite of Home services.

07:09 EDT Entera Bio granted Type C Meeting with FDA for EB613 - Entera Bio announced the execution of the following key milestones: The U.S. Food and Drug Administration has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613, as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022 Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-controlled study, followed by a 6-month open label transition to alendronate for all patients. The study's primary endpoint employs the Foundation for the National Institutes of Health Bone Quality Program total hip Bone Mineral Density as a surrogate endpoint to evaluate fracture risk. FDA re-confirmed that with a well-designed BMD study, EB613 approval would not require a fracture study. In line with her increased executive role since earlier this year, Ms. Miranda Toledano, Entera Board Member and industry veteran with over 20 years of experience succeeds Dr. Spiros Jamas as CEO. During Entera's End of Phase 2 Meeting, FDA's Division of Endocrinology remarked on the FNIH BQP published meta-regression analysis which is based on patient-level BMD and fracture incidence data from more than 22 placebo-controlled fracture endpoint studies across all classes of osteoporosis drugs, including teriparatide. The FNIH BQP data indicate that changes in Total Hip BMD provides a superior surrogate marker of an osteoporosis drug's effects on vertebral, nonvertebral and all site fracture risk. The FNIH BQP BMD data and Surrogate Threshold Effects are in the process of qualification by the FDA to become the first surrogate endpoint for fracture risk reduction. FDA suggested that Entera explore the FNIH BQP STEs and the design of a placebo-controlled study as an alternative to the originally contemplated non-inferiority design versus Forteo. Entera has since submitted to the FDA, as part of its Type C briefing documents, a revised Phase 3 protocol. The study is expected to be an 18-month randomized, double-blind, multicenter study comparing the effects of oral PTH EB613 vs. placebo on BMD in post-menopausal women with osteoporosis at high risk of fracture, followed by a 6-month open-label extension where all patients will be transitioned to alendronate, a standard of care anti-resorptive therapy. Patients will be randomized in a 2:1 ratio to receive blinded treatments with either EB613 2.5mg dose of oral PTH or Placebo. The 6-month extension phase of the study is intended to provide information on the transition from EB613 to a standard anti-resorptive therapy which has been shown to maintain or augment the increases in BMD following injectable PTH therapies, to preserve blinding of the prior therapy and to ensure that patients randomized to the placebo arm also receive an osteoporosis treatment. The primary objective or endpoint of the phase 3 study will evaluate the effect of daily oral EB613 treatment on percent change in Total Hip BMD over 18 months versus placebo. Statistical methods will compare the observed treatment effect compared to pre-defined STEs associated with vertebral fracture, all site fracture and nonvertebral fracture risk reduction. The study will also look at secondary endpoints including changes in lumbar spine and femoral neck BMD and EB613's effects on biochemical markers of bone formation and resorption.

07:07 EDT EDAP TMS announces Focal One HIFU reimbursement raised to urology APC level 6 - EDAP TMS announced that the U.S. Centers for Medicare and Medicaid Services, CMS, has released its proposed outpatient prospective payment system, OPPS, reimbursement rule for calendar year 2023, CY23. For a hospital performing a Focal One HIFU prostate ablation on an outpatient basis, the proposed rule would increase the reimbursement level to an Ambulatory Payment Classification, APC, level 6, as compared to APC level 5 currently. This would result in an increase in reimbursement to a hospital performing a HIFU procedure on a Medicare patient to $8,711 per procedure as a national average, adjusted locally based on the wage index, as compared to $4,506 currently as a national average, adjusted locally based on the wage index. The increase to APC level 6 has positive implications for patients beyond Medicare since many commercial payors have begun to cover focal HIFU for their members. Commercial payment and access policies are influenced by Medicare policy and reimbursement decisions.

07:06 EDT Eton Pharmaceuticals announces FDA approval of ZONISADE - Eton Pharmaceuticals announced that the U.S. Food and Drug Administration has approved ZONISADE. ZONISADE was included in Eton's multi-product neurology oral solution partnership with Azurity Pharmaceuticals announced in February of 2021. Under the agreement, Eton is entitled to receive an additional $5M payment upon the launch of ZONISADE, royalty on net sales, and up to $15M of commercial milestones tied to the combined sales of all three products in the partnership. Azurity Pharmaceuticals will be responsible for the commercialization of ZONISADE, and no marketing expenses will be incurred by Eton.

07:05 EDT Nabriva Therapeutics expands XENLETA presence with agreement with Er-Kim - Nabriva Therapeutics announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA . Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. Er-Kim also may distribute XENLETA to an additional five countries through a Named Patient Usage program. Nabriva will be the exclusive supplier of XENLETA to Er-Kim. Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, commented, "We are excited to partner with Er-Kim, whose local expertise and proven track record uniquely position them for success in making XENLETA available to patients in these territories with community acquired bacterial pneumonia. We look forward to working with Er-Kim as a valued distribution partner to broaden the availability of XENLETA outside the U.S."

07:04 EDT Eliem Therapeutics expects capital to fund operations until mid-2024 - "We are eager to get our ETX-155 program back in the clinic and believe this new plan takes CMC off the critical path and is an effective means to efficiently advance the drug into the Phase 2a MDD trial," said Bob Azelby, Eliem's president and CEO. "We are encouraged by the precedent validation of the GABAA PAM class in multiple large depression trials and believe ETX-155 has the potential to be a clinically differentiated GABAA PAM product candidate. We also look forward to reporting our topline results for ETX-810 in LSRP, an indication for which there is randomized, placebo-controlled precedent clinical data for PEA dietary supplement formulations supporting ETX-810's mechanism of action. With our strong cash position of $149.9 million as of the end of the first quarter of 2022, we believe we have sufficient capital to fund key pipeline catalysts and operations until mid-2024."

07:03 EDT Unicycive enters license, develop agreement with Lee's for renazorb in China - Unicycive Therapeutics announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb to Lee's Pharmaceutical Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings, in Mainland China, Hong Kong, and certain other Asian markets. Renazorb is Unicycive's novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients. "We are delighted to partner with Lee's Pharm for the development and marketing of Renazorb in China, one of the world's largest markets for end-stage renal disease, where we believe our novel phosphate binding agent will bring significant benefit to patients with hyperphosphatemia," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "Lee's Pharm has the clinical, regulatory and commercial expertise in these Asian markets and we are confident this relationship will maximize the market opportunity for our proprietary nanotechnology-based asset in these territories while bringing meaningful benefit to patients. Unicycive owns global rights for Renazorb and by partnering Renazorb in select Asian countries, we begin to unlock its value for patients, physicians and for our shareholders." Under the terms of the agreement, Lee Pharm will be responsible for development, registration filing and approval for Renazorb in the licensed territories. In addition, Lee Pharm will have sole responsibility for the importation of the drug product from Unicycive and for the costs of commercialization of Renazorb in the licensed territories. Unicycive will receive an upfront payment of $1M upon signature and up to $1M in milestone payments upon product launch in China and will be eligible for tiered royalties upon achievement of prespecified regulatory and commercial achievements.

07:03 EDT AerCap Cargo signs lease agreements for six 737-800 Boeing converted freighters - AerCap Holdings N.V. (AER) announced it has signed lease agreements with GOL (GOL) for the lease of six 737-800 Boeing (BA) Converted Freighter aircraft, three of which are scheduled to deliver to GOL in 2022, with the remaining three delivering in 2023. The six 737-800BCF, passenger-to-freighter aircraft, will be operated for a Latin-American e-commerce company, as part of the growth strategy and logistics solution of GOLLOG, GOL's Logistics Business Unit, and will be based in Brazil, flying to destinations across South America. Peter Anderson, Chief Commercial Officer of AerCap, said, "We are very pleased to announce our agreement to lease six 737-800 Boeing Converted Freighters to our longstanding customer GOL. These 737-800BCF's will be a versatile addition to GOL's fleet, allowing them to respond to the increased demand from e-commerce retail businesses in South America. We are delighted to expand our relationship with GOL and wish them every success with these aircraft in the years to come."

07:02 EDT Editas Medicine appoints Mei as SVP, CMO - Editas Medicine (EDIT) announced the appointment of Baisong Mei, M.D., Ph.D., as the Company's Senior Vice President, SVP, and Chief Medical Officer, CMO, effective immediately. Dr. Mei will lead clinical research and drug development for the Company's pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology. Dr. Mei brings to Editas more than 20 years of experience in the biotech and pharmaceutical industry, spanning the entire drug development life cycle across multiple disease areas, including hematology, neurology, and other diseases. Dr. Mei joins Editas Medicine from Sanofi (SNY), where he served as Senior Global Project Head in Rare Disease and Rare Blood Disorders.

06:55 EDT Ra Medical Systems names Brian Conn as interim CFO - Ra Medical Systems announces the appointment of Brian Conn as interim CFO, effective immediately. Conn will serve as the company's Principal Financial Officer and Principal Accounting Officer. Conn has served as a consultant to Ra Medical since May 25. He replaces Will McGuire, who was appointed interim CFO on July 8, following the departure of Andrew Jackson, the company's former CFO, on May 25. McGuire will continue in his positions as CEO and director of the company.

06:51 EDT Bank of America shares drop nearly 2% after reporting Q2 results

06:49 EDT Bank of America reports Q2 FICC revenue $2.3B excluding net DVA - Excluding net DVA, sales and trading revenue up 11% to $4.0 billion; FICC up 19% to $2.3 billion; Equities up 2% to $1.7 billion.

06:36 EDT Air Lease announces lease placement of six new Airbus A220-300 aircraft - Air Lease (AL) announced long-term lease placements for six new Airbus (EADSY) A220-300 aircraft with TAAG Angola Airlines. The aircraft are scheduled to deliver to the airline starting in 2023 through 2024 from ALC's orderbook with Airbus.

06:34 EDT GSK plc announces completion of demerger of Haleon - GSK plc (GSK) has on Monday, July 18, completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. The shares of Haleon plc will be admitted at 8.00 a.m. today to the Premium Listing segment of the Official List and to trading on the Main Market of the London Stock Exchange, or "LSE." It is expected that American Depositary Shares representing shares of Haleon plc, ticker: "NYSE: HLN", will commence "regular-way" trading on the New York Stock Exchange at market open on Friday, July 22. In addition, GSK expects that Haleon ADSs will begin trading on a "when-issued" basis on the NYSE from market open today up to and including Thursday, July 21. Each Haleon ADS represents two Haleon ordinary shares. At the GSK General Meeting on July 6, alongside the demerger, GSK shareholders also approved the consolidation of GSK shares. The GSK Share Consolidation is expected to take place after the market closes today. It is expected that admission and dealings in the new GSK shares on the LSE will commence at 8.00 a.m. on Tuesday, July 19. GSK will provide an update following the completion of the GSK Share Consolidation at around 7.00 a.m. on Tuesday, July 19. The ratio for the GSK Share Consolidation cannot be fixed at this time as it will depend on fluctuations in the volume and price of the GSK shares in the period between 8.00 a.m. and 4.30 p.m. today.

06:30 EDT Roche launches Elecsys HCV Duo immunoassay in CE Mark countries - Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. "Elecsys HCV Duo is the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus antigen and antibody status from a single human plasma or serum sample. This means that the test can be used to detect the early stage of infection, as well as when the patient is recovering from the virus, or showing signs of a chronic infection that may lead to other diseases, such as liver cancer," the company said.

06:24 EDT Assa-Abloy to delay acquisition of Spectrum Brands' HHI unit to June 2023 - Last week, Spectrum Brands stated: "On September 8, 2021, ASSA ABLOY announced it had signed an agreement to acquire the HHI division of Spectrum Brands for a purchase price of MUSD 4,300 on a cash and debt free basis. ASSA ABLOY and Spectrum Brands have agreed to extend their agreement for ASSA ABLOY to acquire the HHI division of Spectrum Brands to June 30, 2023. ASSA ABLOY and Spectrum Brands both remain fully committed to the transaction and confident that they will obtain all required governmental clearances to complete the transaction."

06:12 EDT National Energy Services to acquire minority stake in WDVG - National Energy Services announced that it has agreed to acquire a minority stake in W. D. Von Gonten Engineering, or WDVG,, a premier Reservoir Characterization and Geological & Geophysical, or G&G, laboratory and consulting business formed from the merger of W. D. Von Gonten Laboratories and W. D. Von Gonten & Co. Petroleum Engineering Consulting. This acquisition, valued at approximately four times estimated 2022 EBITDA, was funded mainly through issuing NESR shares valued at $10 per share, and a minority portion of cash. NESR will also have the sole option to acquire additional stake and become the majority owner of WDVG in subsequent years. Meanwhile, NESR will receive state of the art custom laboratory equipment that will ensure completing its vision of having the most advanced Research and Development center in the region focused on unconventional studies in NESR's Oilfield Research Facility in the heart of Saudi Arabia's Dhahran Techno Valley later this year.

06:09 EDT Second Sight announces year four NIH funding of its Orion Trial - Second Sight Medical Products announced that the company received notice from the National Institutes of Health of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant 5UH3NS103442. The NIH released $1.1M of the $6.4M planned five-year grant. The company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.

06:06 EDT Evelo Biosciences names Marella Thorell as CFO, effective September 1 - Evelo Biosciences (EVLO) announced the appointment of Marella Thorell as CFO, effective September 1. Thorell brings more than 25 years of finance and operations experience, having successfully led multiple M&A, licensing, and fundraising transactions for biotechnology companies, as well as having directed public and private company finance teams across diverse global markets and through all stages of clinical development. She most recently served as Chief Accounting Officer of Centessa Pharmaceuticals (CNTA).

06:02 EDT Precision Drilling acquires High Arctic's Well Servicing & Rentals Divisions - Precision Drilling is pleased to announce that it has entered into an asset purchase agreement to acquire the well servicing business and associated rentals assets of High Arctic Energy Services for an aggregate purchase price of $38.2M, payable in cash. Precision adds to its Canadian well servicing operation a fleet of 80 service rigs (51 marketed and 29 inactive). The Transaction provides Precision with rental assets, ancillary support equipment, inventories and spares, and six additional operating facilities in key basins, four of which are owned. Additional Transaction highlights include: Acquisition of high-quality assets with skilled and experienced field personnel and a strong customer following; Combined business will have marketed fleet of 134 service rigs and represents approximately 20% of Canadian industry well service activity; Leverages Precision Well Services' leading operational scale, generating significant synergies including expected annual operating cost savings of $5M annually, realizable within one year; and Accretive acquisition that supports Precision's long-term capital allocation and de-leveraging plan through increased cash flow generation. Precision is acquiring the Well Servicing and Rentals divisions (excluding working capital) for $38.2M in cash. An initial payment of $10.2M will be made at closing, with the remaining balance due in January 2023. The Transaction is subject to customary commercial closing conditions and is expected to close before the end of July.

05:49 EDT Twitter board urges investors to approve sale to Musk in revised proxy filing - In an SEC filing on Friday, Twitter told investors that approving the company's sale to Elon Musk is the only remaining step in satisfying the merger agreement. "Adoption of the merger agreement by our stockholders is the only remaining approval or regulatory condition to completing the merger under the merger agreement, and is an important and required step for our stockholders to receive the merger consideration," Twitter said in an updated proxy filing with the SEC. The company added that "We are committed to closing the merger on the price and terms agreed upon with Mr. Musk." Reference Link

05:22 EDT Parker-Hannifin segment announces agreement with the Defense Logistics Agency - Parker Aerospace, a business segment of Parker Hannifin, announced an agreement with the Defense Logistics Agency and the U.S. Air Force for a five-year performance-based logistics, or PBL, contract covering hydraulic equipment across five key Air Force platforms. Under the sustainment agreement, Parker Aerospace will provide supply chain, engineering and field service support at the Ogden Air Logistics Complex at Hill Air Force Base in Utah under pre-negotiated fixed rates.

05:17 EDT Triumph Group signs five-year licensing agreement extension with Ruag - Triumph Group announced that its geared solutions business has signed a five-year licensing agreement extension with Ruag, a company that specializes in aerospace engineering and defense, for continued sustainment support on the F/A-18 A-D Aircraft Mounted Accessory Drive, or AMAD. With this licensing agreement, Triumph and Ruag will collaborate to provide testing, repair, and overhaul support for the F/A-18 AMAD military applications. Ruag's facility in Interlaken/Wilderswil, Switzerland supports international military operators by utilizing Triumph's repair procedures and spares pool to support the F/A-18 AMAD product line. Through the license arrangement, Triumph allows for the sustainment of all non-US military F/A-18 AMAD's to be maintained at Ruag, ensuring worldwide readiness of F/A-18 A-D variants for international operators.

05:12 EDT Curtiss-Wright awarded Airbus contract for custom electric actuation technology - Curtiss-Wright (CW) announced that it has been selected by Airbus (EADSY) to provide custom electric actuation technology for the Main Deck Cargo Door on the future Airbus A350F freighter aircraft. The A350F, a variant of the Airbus A350, will be the first wide body freighter aircraft built with a majority of composite materials. Under the contract, Curtiss-Wright will provide Airbus with an electro-mechanical actuation solution that features rotary and linear actuators, alongside control and power electronics, to open, close, latch and lock the A350F's Main Deck Cargo Door. Curtiss-Wright's actuation solution includes a high-voltage DC architecture that minimizes weight, offers improved reliability over legacy systems, and incorporates health monitoring functions.

05:06 EDT Tuniu regains compliance with Nasdaq - Tuniu announced that it has received a notification letter from the listing qualifications department of Nasdaq informing the company that it has regained compliance with Nasdaq Listing Rule 5450.